SBIR/STTR Research Award
Innate Defense Regulator Peptide as a Therapeutic for Acute Pneumonic Melioidosis
Award amount
$300,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Soligenix, Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- GVD4XBVYD9J5
- Solicitation number
- PA13-234
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): This proposal describes development of an immunomodulatory peptide that targets the host defense system for treatment of acute pneumonic melioidosis. The disease is caused by Burkholderia pseudomallei (Bps), a non-spore-forming motile saprophytic bacterium that can be transmitted from the soil to humans by inhalation, through cuts in the skin and by ingestion. Bps is classified as a category B biological threat agent by U.S. Department of Health and Human Services (DHHS) and in the 2012 Health Emergency Medical Countermeasure Enterprise (PHEMCE) Strategy document because of its infectivity by the aerosol route and environmental robustness. Furthermore, Bps is endemic in Southeast Asia, Brazil, Africa, the Middle East, and Northern Australia. Bps is intrinsically resistant to antibiotics normally used for first line treatment of Gram-negative septicemia, accounting for high mortality in endemic regions. Preventative or therapeutic vaccinations are not yet available, i
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP
- "Dusquetide for the treatment of oral mucositis in the pediatric population"
- Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma
- SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer
- SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
11 SBIR/STTR records share this UEI (2003–2021). Reported award amounts total $7,136,544. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Health and Human Services